Uterine Fibroids Toolkit: A Patient Empowerment Guide

While an estimated 26 million women ages 15-50 in United States have uterine fibroids, these statistics about fibroids are often underestimated. 

Uterine fibroids (leiomyomas) are tumors made of smooth muscle and fibrous connective tissue that arise from the uterus and are one of the most common gynecological conditions nationwide.

Fibroids can develop in any girl or woman after the onset of her menstrual cycle. Although fibroids are most commonly diagnosed in individuals in their 30s and 40s, they can occur in adolescents and postmenopausal women, particularly those using hormone therapy. Fibroids tend to increase during the reproductive years and then shrink after menopause. These growths are non-malignant and are not associated with an increased risk of uterine cancer, but they can result in mild to severe side effects and can affect one’s quality of life.

SWHR’s toolkit is designed to empower individuals with uterine fibroids in navigating their care.

The toolkit provides easy-to-understand information on gynecological health, guidance on uterine fibroid diagnosis and treatment, and tips for interacting with your health care provider. The toolkit aims to facilitate productive conversations between patients and health care providers so people with uterine fibroids can get the care they need.

DOWNLOAD THE UTERINE FIBROIDS TOOLKIT

While an estimated 26 million women ages 15-50 in United States have uterine fibroids, these statistics about fibroids are often underestimated. 

Uterine fibroids (leiomyomas) are tumors made of smooth muscle and fibrous connective tissue that arise from the uterus and are one of the most common gynecological conditions nationwide.

Fibroids can develop in any girl or woman after the onset of her menstrual cycle. Although fibroids are most commonly diagnosed in individuals in their 30s and 40s, they can occur in adolescents and postmenopausal women, particularly those using hormone therapy. Fibroids tend to increase during the reproductive years and then shrink after menopause. These growths are non-malignant and are not associated with an increased risk of uterine cancer, but they can result in mild to severe side effects and can affect one’s quality of life.

SWHR’s toolkit is designed to empower individuals with uterine fibroids in navigating their care.

The toolkit provides easy-to-understand information on gynecological health, guidance on uterine fibroid diagnosis and treatment, and tips for interacting with your health care provider. The toolkit aims to facilitate productive conversations between patients and health care providers so people with uterine fibroids can get the care they need.

DOWNLOAD THE UTERINE FIBROIDS TOOLKIT

What’s in the Toolkit?

You can access the entire Uterine Fibroids Toolkit above or download these individual toolkit pieces:

For more information, see the Uterine Fibroids Toolkit’s Glossary, Quick Links, and References.

The toolkit is a project of SWHR’s Uterine Fibroids Program, which convenes a diverse group of researchers, health care providers, patients, and health care thought leaders working to educate and engage society about the burden of fibroids, which significantly impact the lives of the women.

SWHR thanks AbbVie, Myovant | Pfizer, and Roche for their support of this educational work.